Background and Aims: The pivotal trial of the MiniMed™ 780G system showed that optimized settings of active insulin time (2 hours) and target glucose (100mg/dL) improved glycemic outcomes.1 This study analyzed real-world glycemic outcomes of individuals with T1D in Chile, 6 months after AHCL initiation with different settings.
Methods: Data from 37 MiniMed™ 780G system users (aged 5-76 years, mean±SD of 29.3±19.3 years) at 12 centers throughout Chile were prospectively collected and analyzed. Effects of active insulin time (AIT) and glucose target on mean GMI, TIR (70-180mg/dL) , time at <70mg/dL (TBR) and time at >180mg/dL (TAR) were determined using 14 days of sensor glucose data pre-AHCL and at 180 days post-AHCL initiation.
Results: Overall TIR increased from 74.1% to 78.4% (p<0.01) , and mean TBR and GMI were 2.7% and 6.7% at study end, respectively. Individuals (N=23) with optimized settings achieved the highest TIR (80.1%) and lowest TBR (2.6%) (Figure 1) .
Conclusion: In this real-world data analysis, MiniMed™ 780G system users who optimized their active insulin time and target glucose settings achieved the highest TIR and lowest TBR.
M.Castro: Employee; Medtronic. C.Carrasco bonilla: Employee; Medtronic. J.C.Leon macedo: Employee; Medtronic. M.Gutierrez: Employee; Medtronic. Z.C.Valera lopez: Employee; Medtronic. A.Daghero: Employee; Medtronic.